Aminath Mariya

Aminath Mariya

Higher Degree by Research Candidate

Adelaide Law School

Faculty of Arts, Business, Law and Economics


Mariya is a PhD researcher at the Adelaide Law School, University of Adelaide.

Mariya's current research examines the legislation regulating medical devices and explores whether the current framework providing for the regulation of medical innovations and technology adequately safeguard patients from avoidable medical device related harm. In addition to her research interests in medical law and bioethics, Mariya is also interested in understanding regulations and policies governing emerging technologies, especially in the areas of artificial intelligence and health law policies.

As a medical law researcher concerned with issues relating to medical technology and patient safety, Mariya has presented her research at the Australasian Association of Bioethics & Health Law (AABHL) Conferences in 2021 and 2019. Mariya is also a member of the Health Consumer Advocacy Network SA (Health CAN SA) which provides an independent health consumer voice in South Australia and advocates for health and human rights of all South Australians.

Mariya is a member of the Bar Council of Maldives since 2001. She has worked both in house and as a Legal Consultant for corporate clients in the Maldives. Outside of legal practice, Mariya has experience working as a Legal Conference Producer at LexisNexis Brisbane, Reed Elsevier and as a Subject Outline Developer for a Master of Science in Social Policy degree provided by the Maldives National University, College of Open Learning & UNICEF.

Post-market reporting of medical device adverse events play a significant role in apprising safety and performance of medical devices maintained on the Australian Register of Therapeutic Goods. Current law assigns a duty to report medical device adverse events only to the sponsor and manufacturer of the medical device. The regulator’s ability to execute its legislative function of establishing and maintaining a system to achieve safety, quality and efficiency of domestically available therapeutic goods is a public interest function. Current legislative provisions relating to post-market reporting of medical device adverse events create an environment in which the regulator’s ability to meet this important public interest function is left susceptible to the self-interests of the very industry it is appointed to regulate. My research contends that to achieve patient safety and mitigate avoidable harm from medical device adverse events, the post market reporting system for medical device adverse events must be reconsidered so that key health care delivery participants have a legislatively recognised duty to contribute towards medical device adverse event data.


Connect With Me
External Profiles